
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


ICU Medical Inc (ICUI)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: ICUI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $186.2
1 Year Target Price $186.2
3 | Strong Buy |
2 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.99% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.33B USD | Price to earnings Ratio - | 1Y Target Price 186.2 |
Price to earnings Ratio - | 1Y Target Price 186.2 | ||
Volume (30-day avg) 6 | Beta 0.89 | 52 Weeks Range 117.92 - 196.26 | Updated Date 07/6/2025 |
52 Weeks Range 117.92 - 196.26 | Updated Date 07/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.87% | Operating Margin (TTM) 4.89% |
Management Effectiveness
Return on Assets (TTM) 1.79% | Return on Equity (TTM) -4.62% |
Valuation
Trailing PE - | Forward PE 20.66 | Enterprise Value 4644162747 | Price to Sales(TTM) 1.38 |
Enterprise Value 4644162747 | Price to Sales(TTM) 1.38 | ||
Enterprise Value to Revenue 1.92 | Enterprise Value to EBITDA 16.67 | Shares Outstanding 24611900 | Shares Floating 23848229 |
Shares Outstanding 24611900 | Shares Floating 23848229 | ||
Percent Insiders 3.04 | Percent Institutions 101.79 |
Upturn AI SWOT
ICU Medical Inc

Company Overview
History and Background
ICU Medical, Inc. was founded in 1984. It initially focused on developing and marketing needlefree IV connectors and has grown through product innovation and strategic acquisitions to become a global player in infusion therapy and critical care products.
Core Business Areas
- Infusion Consumables: Includes IV sets, solutions, and administration devices used to deliver fluids and medications to patients.
- Infusion Systems: Encompasses infusion pumps and related software used to precisely control the delivery of fluids and medications.
- Medication Delivery: Includes closed system transfer devices (CSTD) and other products used to safely prepare and administer hazardous drugs.
- Other: Other solutions related to IV access, critical care monitoring, and patient safety.
Leadership and Structure
Vivek Jain serves as the Chief Executive Officer. The company has a board of directors and operates with a functional organizational structure, with departments dedicated to research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- IV Solutions: These include a broad range of solutions like saline, dextrose, and lactated Ringer's used in IV therapy. Competition includes Baxter, B. Braun, and Fresenius Kabi. Market share data is difficult to pinpoint exactly, but the combined market represents billions in yearly sales. ICU Medical is a key player in the IV solutions market but not the leading single player.
- Infusion Pumps: ICU Medical offers various infusion pumps used to deliver fluids and medications. Competitors include Baxter and BD. Market share data is fragmented, but the global infusion pump market is significant and split across a few key players. ICU Medical's marketshare is a distant third in this space.
- Closed System Transfer Devices (CSTDs): CSTDs protect healthcare workers from exposure to hazardous drugs during compounding and administration. Key competitor in this space is BD. This is one of ICU Medical's stronger sectors where they are a clear leader.
Market Dynamics
Industry Overview
The medical device industry is characterized by technological innovation, stringent regulatory requirements, and increasing demand for advanced healthcare solutions. Trends include connected devices, personalized medicine, and a focus on patient safety.
Positioning
ICU Medical is positioned as a leading provider of infusion therapy and critical care products. Its competitive advantages include a broad product portfolio, a strong reputation for quality and innovation, and a global distribution network.
Total Addressable Market (TAM)
The TAM is estimated to be in the tens of billions of USD. ICU Medical is well-positioned to capture a significant portion of the TAM, particularly in its core infusion therapy and medication delivery segments.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Broad product portfolio
- Global distribution network
- Focus on innovation
- Strong financial performance
Weaknesses
- Reliance on a few key products
- Integration challenges related to acquisitions
- Exposure to regulatory risks
- Dependence on hospital capital spending
Opportunities
- Expanding into emerging markets
- Developing new products and technologies
- Acquiring complementary businesses
- Partnering with other healthcare providers
Threats
- Increasing competition
- Pricing pressures
- Technological obsolescence
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- BAX
- BDX
- FMS
Competitive Landscape
ICU Medical competes with larger medical device companies. Their strengths include focused expertise and specialty products, while their disadvantages include smaller scale and less diversification.
Major Acquisitions
Smiths Medical
- Year: 2022
- Acquisition Price (USD millions): 2350
- Strategic Rationale: Expanded ICU Medical's global reach and product portfolio in infusion therapy and vascular access.
Growth Trajectory and Initiatives
Historical Growth: ICU Medical has grown through organic product development and strategic acquisitions.
Future Projections: Future growth projections depend on analyst estimates and market conditions. See analyst reports for details.
Recent Initiatives: Recent initiatives include new product launches, expansion into new markets, and strategic acquisitions.
Summary
ICU Medical is a reputable medical device company that is positioned in the infusion market. With the acquisition of Smiths Medical, they have an expanded offering that will need to be integrated. While they face stiff competition, their continued focus on innovation and acquisitions sets them up for future growth. The company needs to be mindful of the market leaders in infusion products. There also need to be more revenue-generating avenues outside of M&A.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Industry Reports
- Analyst Reports
- Press Releases
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ICU Medical Inc
Exchange NASDAQ | Headquaters San Clemente, CA, United States | ||
IPO Launch date 1992-03-31 | CEO & Chairman of the Board Mr. Vivek Jain | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 15000 | Website https://www.icumed.com |
Full time employees 15000 | Website https://www.icumed.com |
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. It offers infusion therapy products, such as needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.